Zacks Investment Research downgraded shares of Aratana Therapeutics (NASDAQ:PETX) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning.
According to Zacks, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. “
A number of other analysts also recently issued reports on the stock. CL King initiated coverage on shares of Aratana Therapeutics in a research report on Wednesday, December 27th. They set a neutral rating for the company. HC Wainwright initiated coverage on shares of Aratana Therapeutics in a research report on Friday, November 17th. They set a buy rating and a $10.00 target price for the company. Jefferies Group reissued a buy rating and set a $8.00 target price on shares of Aratana Therapeutics in a research report on Friday, November 3rd. Stifel Nicolaus reaffirmed a hold rating and issued a $6.00 price objective on shares of Aratana Therapeutics in a research report on Monday, December 18th. Finally, ValuEngine downgraded shares of Aratana Therapeutics from a sell rating to a strong sell rating in a research report on Sunday, December 31st. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. Aratana Therapeutics currently has a consensus rating of Hold and an average target price of $8.55.
Shares of Aratana Therapeutics (PETX) opened at $4.75 on Wednesday. The stock has a market cap of $211.13, a P/E ratio of -3.28 and a beta of 3.37. Aratana Therapeutics has a 1 year low of $4.67 and a 1 year high of $8.12. The company has a current ratio of 3.42, a quick ratio of 3.08 and a debt-to-equity ratio of 0.26.
Aratana Therapeutics (NASDAQ:PETX) last posted its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.03. The firm had revenue of $6.16 million during the quarter, compared to the consensus estimate of $6.47 million. Aratana Therapeutics had a negative net margin of 358.55% and a negative return on equity of 48.79%. The company’s revenue was up 1440.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.38) EPS. analysts expect that Aratana Therapeutics will post -1.03 earnings per share for the current year.
In other Aratana Therapeutics news, insider Craig A. Tooman sold 30,000 shares of the stock in a transaction that occurred on Thursday, January 11th. The shares were sold at an average price of $5.27, for a total value of $158,100.00. Following the completion of the sale, the insider now owns 75,024 shares of the company’s stock, valued at $395,376.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Peter Steven St sold 50,000 shares of the stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $7.00, for a total transaction of $350,000.00. Following the completion of the sale, the insider now directly owns 529,359 shares of the company’s stock, valued at approximately $3,705,513. The disclosure for this sale can be found here. Insiders sold 1,087,032 shares of company stock valued at $6,344,891 in the last ninety days. 5.20% of the stock is owned by corporate insiders.
Large investors have recently modified their holdings of the business. Voya Investment Management LLC grew its position in Aratana Therapeutics by 22.7% in the second quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 3,610 shares in the last quarter. ProShare Advisors LLC boosted its stake in shares of Aratana Therapeutics by 7.2% during the 2nd quarter. ProShare Advisors LLC now owns 25,322 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 1,709 shares during the last quarter. Parametric Portfolio Associates LLC boosted its stake in shares of Aratana Therapeutics by 6.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 30,127 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 1,875 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Aratana Therapeutics by 25.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,176 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 6,898 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of Aratana Therapeutics by 16.4% during the 2nd quarter. Rhumbline Advisers now owns 48,214 shares of the biopharmaceutical company’s stock valued at $349,000 after buying an additional 6,800 shares during the last quarter. 73.76% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Aratana Therapeutics (PETX) Cut to “Sell” at Zacks Investment Research” was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.thelincolnianonline.com/2018/01/20/aratana-therapeutics-petx-cut-to-sell-at-zacks-investment-research.html.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.